Multiple Myeloma Therapeutics Market Market Analysis

Treatment Type (Chemotherapy, Targeted Therapy, Immunomodulating Agents, Stem Cell Transplantation, Radiation Therapy)

Targeted therapy segment is projected to account for multiple myeloma therapeutics market share of more than 33.6% by the end of 2037. The disease-specific pathways of these drugs are designed to increase the rate of survival for cancer patients. This further implies in broadened usage of targeted therapies in various treatment processes. The improved outcomes for multiple myeloma are inspiring manufacturers to invest in R&D to expand available options. In June 2024, Mission Bio launched a multi-omics solution, Tapestri to provide precise insights for R&D in multiple myeloma therapeutics. This product suite will help to classify cell types in the process of identifying immunotherapeutic targets including BCMA.

Route of Administration (Oral, Parenteral)

Based on the route of administration, the oral segment is estimated to capture a significant share of the multiple myeloma therapeutics market. The growth is propelled by patient adherence and convenient usage of oral supplements. These therapies are being increased in efficacy by combining them with other treatments. For instance, in October 2024, Jhonson & Jhonson received extensive approval for DARZALEX SC formulation for 1^st stage myeloma patients. The quadruplet therapy can be used with a combination of bortezomib, lenalidomide, and dexamethasone. The new oral therapy is examined by the PERSEUS study, ensuring a 58% reduction in disease progression or mortality. Such innovative ways of taking supplements are creating the scope to develop more personalized regiments.

Our in-depth analysis of the global market includes the following segments:

Treatment Type	Chemotherapy Targeted therapy Immunomodulating agents Stem cell transplantation Radiation therapy Others
Route of Administration	Oral Parenteral
Disease Type	Active Multiple Myeloma Smoldering Multiple Myeloma
End use	Hospitals Specialty clinics Homecare settings Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the multiple myeloma therapeutics market was over USD 27.2 billion.

The market size for the multiple myeloma therapeutics market is projected to reach USD 58.5 billion by the end of 2037 expanding at a CAGR of 6.6% during the forecast period i.e., between 2025-2037.

The major players in the market as Service Providers are Cleveland Clinic, Dana-Farber Cancer Institute, Inc., Mayo Foundation for Medical Education and Research (MFMER), MD Anderson Cancer Center, Takeda Pharmaceutical Company Limited, and others.

In terms of treatment type, the targeted therapy segment is anticipated to garner the largest market share of 33.6% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 47.8% by the end of 2037 and provide more business opportunities in the future.

Multiple Myeloma Therapeutics Market Market Analysis